Butterfly's chip ships inside Mendaera's robot while insiders sold $31.95 million

Mendaera's FDA-cleared Focalist robot, a handheld system for guiding needles in vascular access, nerve blocks and organ access, went commercially available with a customized Butterfly iQ3 probe on 1 October ¹. Butterfly calls Mendaera the first Butterfly Embedded partner to commercialize↗, which makes this week the first time the licensing thesis has a product on a shelf ¹. No financial terms were disclosed.

The rest of the pipeline sits earlier. Merge Labs, launched in January with $252 million from investors including OpenAI, Bain Capital and Gabe Newell and with Sam Altman on its founding team, is building brain-computer interfaces on the chip ². Its multi-year licence pays Butterfly upfronts, milestones and technology-access fees; royalties are only "expected" ². The Midjourney Medical full-body imaging build has not shipped ³.

Embedded already books revenue, $5.7 million in the first quarter, up 147%↗, driven primarily by Midjourney ⁴. That is development money. The royalties the street is underwriting start with a robot that holds needles.

The ledger beside the launch

Insiders sold 4,708,246 shares for $31,950,688 in the three months to early October↗ ⁵. Director Jonathan Rothberg cut his stake 95.67%, selling 1,195,857 shares at $6.60 under a pre-arranged 10b5-1 plan, and another insider's sale covered tax withholding ⁵. One director swam the other way: Louise Phanstiel bought 115,200 shares at $8.68 on 14 August↗, $999,936 in total ⁶. Plan sales and tax sales are mechanical. The direction is still one-way.

The street pays for the chip, not the royalties

Q2 revenue of $32.61 million beat the $29.16 million consensus and cleared the top of management's own $27 million to $31 million guide, with gross margin up to 71.4% from 63.7% and the quarterly adjusted EBITDA loss narrowed to $1.4 million from $6.2 million ⁵⁴³. The full year still carries a guided $19 million to $23 million adjusted EBITDA loss against $124.7 million of June cash, at a $2.38 billion market cap ³⁵⁷.

Needham's 22 September initiation↗ drove a 22% single-day move to $9.93 ³. Evercore followed on 29 September with $15 against an $8.54 consensus; TD Cowen and Needham sit at $10, and Weiss Ratings still carries a "sell (d-)" from 3 August ⁶⁵. The stock gapped from a $9.15 close to a $9.69 open on 29 September and last traded at $9.54, inside a one-year range of $1.87 to $10.05 ⁶⁵.

The counter and the tell

Institutions lean in: 33 hedge funds held the stock in the second quarter against 26 a quarter earlier↗, and BlackRock added about 17.9% to its position ⁸. The short side is sizeable too: 32.18 million shares, about 15% of the float, were sold short at the 14 August settlement ⁸. One columnist's line on the unshipped half of the story, "R&D burn dressed up as a platform↗", names the standing risk: GE, Philips and Siemens own the installed bases ⁷. Both companies demo at ACEP26 in Chicago, 5 to 7 October ¹.

The tell is the first disclosed per-unit royalty from a partner's shipping product. The margins prove the chip. The register has yet to prove the business.